Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Viridian Therapeutics Highlights 2025 Corporate Priorities Following Positive Phase 3 Topline Data in Thyroid Eye Disease
Viridian Therapeutics, Inc. (NASDAQ: VRDN) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $38.00 price target on the stock.
Viridian Therapeutics, Inc. (NASDAQ: VRDN) had its "equal weight" rating re-affirmed by analysts at Wells Fargo & Company. They now have a $27.00 price target on the stock.
Viridian Therapeutics, Inc. (NASDAQ: VRDN) had its price target raised by analysts at Royal Bank of Canada from $44.00 to $47.00. They now have an "outperform" rating on the stock.